羟丁酸钠(Sodium Oxybate) - 药物靶点：GABAB receptor_在研适应症：猝倒症，发作性睡病，白天过度嗜睡_专利_临床

概要

基本信息

药物类型

小分子化药

别名

GHB、Oxybate sodium、Sodium gammahydroxybutyrate

+ [7]

靶点

GABAB receptor

作用机制

GABAB receptor激动剂(γ-氨基丁酸B受体激动剂)

治疗领域

神经系统疾病其他疾病

在研适应症

猝倒症发作性睡病白天过度嗜睡+ [1]

非在研适应症

戒酒儿童交替性偏瘫暴食症+ [8]

原研机构

Jazz Pharmaceuticals Plc

在研机构

UCB Pharma Ltd.

Avadel Pharmaceuticals PlcAvadel CNS Pharmaceuticals LLC

+ [2]

非在研机构

Jazz Pharmaceuticals PlcD&A Pharma SAS

最高研发阶段批准上市

首次获批日期

美国 (2002-07-17),

发作性睡病

最高研发阶段(中国)-

特殊审评孤儿药 (美国)、孤儿药 (欧盟)

登录后查看首次获批时间轴

结构

分子式C4H8NaO3

InChIKeyWFBCFGRDCIMEAM-UHFFFAOYSA-N

CAS号502-85-2

关联

73

项与羟丁酸钠相关的临床试验

ISRCTN11236443 / Recruiting临床3期

Sodium oxybate as a potential new treatment for catatonia in patients with depression, bipolar disorder or a psychotic disorder, a randomized controlled trial. The Laborit study

开始日期2024-07-01

申办/合作机构-

NCT05837091 / Recruiting临床4期

Impact of Low Sodium Oxybate on Total Sleep Time in Patients With Idiopathic Hypersomnia

Low sodium oxybate has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic hypersomnia. In this study, the researchers want to learn how low sodium oxybate impacts ability of people diagnosed with idiopathic hypersomnia to sleep for long periods of time. In addition, this study will use novel tools to determine when an individual is awake or asleep.

开始日期2024-02-14

申办/合作机构

Mayo Clinic

ChiCTR2300078594 / Recruiting临床3期IIT

Effect of sodium oxybate on sleep quality and neuro-cognitive funtion of elderly patients

开始日期2023-12-15

申办/合作机构-

100 项与羟丁酸钠相关的临床结果

登录后查看更多信息

100 项与羟丁酸钠相关的转化医学

登录后查看更多信息

100 项与羟丁酸钠相关的专利（医药）

登录后查看更多信息

2,121

项与羟丁酸钠相关的文献（医药）

2024-05-01·Journal of clinical anesthesia

Effects of intraoperative sodium oxybate infusion on post-operative sleep quality in patients undergoing gynecological laparoscopic surgery: A randomized clinical trial

Article

作者: Zheng, Lanlan ; Zhao, Ping ; Xue, Hang ; Xing, Tianyi ; Wu, Ziyi ; Zhang, Xinping ; Zhao, Anqi ; Cui, Meiying ; Wang, Fang

STUDY OBJECTIVE:

Post-operative sleep quality is an important factor that influences post-operative recovery. Sodium oxybate has been used to treat sleep disturbances associated with various pathological conditions. However, whether intraoperative intravenous infusion of sodium oxybate improves post-operative sleep quality is unknown. This study aimed to examine the effects of sodium oxybate on the post-operative sleep quality of patients who underwent gynecological laparoscopic surgery.

DESIGN:

A single-center, prospective, two-arm, double-blinded randomized controlled trial.

SETTING:

The Shengjing Hospital of China Medical University in Liaoning, China.

PATIENTS:

We enrolled 180 adult patients (90 for each group) undergoing elective gynecological laparoscopic surgery, and 178 patients (89 for each group) were included in the final analysis.

INTERVENTIONS:

Patients were randomly allocated in a 1:1 ratio to receive either sodium oxybate (30 mg kg^-1) or an equivalent volume of saline after intubation. The patients, anesthetists, and follow-up staff were blinded to group assignment.

MEASUREMENTS:

The primary outcome was sleep quality measured using the Richards-Campbell Sleep Questionnaire (RCSQ) on post-operative days (PODs) one and three. Secondary outcomes included post-operative pain measured using the visual analog scale, sleep quality at one and three months post-operatively measured using the Pittsburgh Sleep Quality Index, and factors associated with post-operative sleep quality.

MAIN RESULTS:

Analysis with generalized estimating equations showed that sodium oxybate significantly improved post-operative sleep quality, as represented by increased total RCSQ scores (mean difference (95% CI); 9 (2, 16), P = 0.010) over PODs one and three. There was no difference in post-operative pain between the two groups over PODs one and three or in post-operative sleep quality over one and three months post-operatively. Age, surgery type, start time of surgery, and use of sufentanil-based patient-controlled intravenous analgesia were significantly associated with post-operative sleep quality.

CONCLUSIONS:

Intraoperative sodium oxybate infusion improved post-operative sleep in patients who underwent gynecological laparoscopic surgery.

TRIAL REGISTRATION:

Chinese Clinical Trial Registry, Clinical trial number: ChiCTR2200061460.

2024-03-01·Journal of veterinary pharmacology and therapeutics

Pharmacokinetics of gamma‐hydroxybutyric acid in 6‐week‐old swine (Sus scrofa domesticus) after intravenous and oral administration

Article

作者: Van Uytfanghe, Katleen ; Devreese, Mathias ; Schauvliege, Stijn ; Cuypers, Charlotte ; Stove, Christophe

Abstract:

Sedative as well as protective effects during hypoxia have been described for gamma‐hydroxybutyric acid (GHB). Six swine (Sus scrofa domesticus) of 6 weeks old were administered NaGHB at a dose of 500 mg/kg intravenously (IV) and 500 and 750 mg/kg orally (PO) in a triple cross‐over design. Repeated blood sampling was performed to allow pharmacokinetic analysis of GHB. Whole blood concentration at time point 0 after IV administration was 1727.21 ± 280.73 μg/mL, with a volume of distribution of 339.45 ± 51.41 mL/kg and clearance of 164.94 ± 47.05 mL/(kg h). The mean peak plasma concentrations after PO administration were 326.57 ± 36.70 and 488.01 ± 154.62 μg/mL for 500 mg/kg and 750 mg/kg, respectively. These were recorded at 1.42 ± 0.72 and 1.58 ± 0.58 h after PO dose for GHB 500 mg/kg and 750 mg/kg, respectively. The elimination half‐life for IV and PO 500 mg/kg and PO 750 mg/kg dose was respectively 1.33 ± 0.30, 1.16 ± 0.31 and 1.11 ± 0.33 h. The bioavailability (F) for PO administration was 45%. No clinical adverse effects were observed after PO administration. Deep sleep was seen in one animal after IV administration, other animals showed head pressing and ataxia.

2024-02-01·Sleep medicine

Effects of oxybate dose and regimen on disrupted nighttime sleep and sleep architecture

Review

作者: Plazzi, Giuseppe ; Black, Jed ; Dauvilliers, Yves ; Roth, Thomas ; Bogan, Richard K

Many components of sleep are disrupted in patients with narcolepsy, including sleep quality, sleep architecture, and sleep stability (ie, frequent awakenings/arousals and frequent shifts from deeper to lighter stages of sleep). Sodium oxybate, dosed twice nightly, has historically been used to improve sleep, and subsequent daytime symptoms, in patients with narcolepsy. Recently, new formulations have been developed to address the high sodium content and twice-nightly dosing regimen of sodium oxybate: low-sodium oxybate and once-nightly sodium oxybate. To date, no head-to-head trials have been conducted to compare the effects of each oxybate product. This review aims to give an overview of the existing scientific literature regarding the impact of oxybate dose and regimen on sleep architecture and disrupted nighttime sleep in patients with narcolepsy. Evidence from 5 key clinical trials, as well as supporting evidence from additional studies, suggests that sodium oxybate, dosed once- and twice-nightly, is effective in improving sleep, measures of sleep architecture, and disrupted nighttime sleep in patients with narcolepsy. Direct comparison of available efficacy and safety data between oxybate products is complicated by differences in trial designs, outcomes assessed, and statistical analyses; future head-to-head trials are needed to better understand the advantage and disadvantages of each agent.

135

项与羟丁酸钠相关的新闻（医药）

2024-06-27

·GlobeNewswire-Health Care

Avadel Pharmaceuticals to Join Russell 3000® Index

DUBLIN, June 27, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted Friday, May 24, 2024. “We are proud to be included in the widely tracked Russell Indexes, which represents another important milestone for our company,” said Greg Divis, Chief Executive Officer of Avadel Pharmaceuticals. “We look forward to the enhanced visibility that inclusion in the Russell Indexes offers as we advance our ongoing commercial launch of LUMRYZ and aim to create long-term value for our stockholders.” The annual Russell U.S. Indexes reconstitution captures the 4,000 largest U.S. stocks as of April 30, 2024, ranking them by total market capitalization. Membership in the U.S. all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the small-cap Russell 2000® Index or the large-cap Russell 1000® Index as well as the appropriate growth and value style indexes. FTSE Russell, a prominent global index provider, determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to the FTSE Russell data, as of the end of December 2023, about $10.5 trillion in assets are benchmarked against the Russell US Indexes. For more information on the Russell 3000® Index and the Russell indexes reconstitution, go to the "Russell Reconstitution" section on the FTSE Russell website. About Avadel Pharmaceuticals plc Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Avadel’s commercial product, LUMRYZ™, was approved by the U.S. Food & Drug Administration (FDA) as the first and only once-at-bedtime oxybate for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. For more information, please visit www.avadel.com. Cautionary Disclosure Regarding Forward-Looking Statements This press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements relate to our future expectations, beliefs, plans, strategies, objectives, results, conditions, financial performance, prospects or other events. Such forward-looking statements include, but are not limited to, expectations regarding the success of the commercialization of LUMRYZ and the potential benefits conferred by the Company’s inclusion in the Russell 3000 Index. In some cases, forward-looking statements can be identified by use of words such as “will,” “may,” “could,” “believe,” “expect,” “look forward,” “on track,” “guidance,” “anticipate,” “estimate,” “project,” “next steps” and similar expressions and the negatives thereof (if applicable). The Company’s forward-looking statements are based on estimates and assumptions that are made within the bounds of our knowledge of our business and operations and that we consider reasonable. However, the Company’s business and operations are subject to significant risks, and, as a result, there can be no assurance that actual results and the results of the company’s business and operations will not differ materially from the results contemplated in such forward-looking statements. Factors that could cause actual results to differ from expectations in the Company’s forward-looking statements include the risks and uncertainties described in the “Risk Factors” section of Part I, Item 1A of the Company’s most recent Annual Report on Form 10-K and subsequent filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made and are not guarantees of future performance. Accordingly, you should not place undue reliance on forward-looking statements. The Company does not undertake any obligation to publicly update or revise our forward-looking statements, except as required by law. Investor Contact:Courtney MogerleyPrecision AQCourtney.Mogerley@precisionAQ.com (212) 698-8687 Media Contact:Lesley StanleyReal Chemistrylestanley@realchemistry.com (609) 273-3162

2024-06-27

·BioSpace

Avadel Pharmaceuticals to Join Russell 3000® Index - June 27, 2024

DUBLIN, June 27, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted Friday, May 24, 2024. “We are proud to be included in the widely tracked Russell Indexes, which represents another important milestone for our company,” said Greg Divis, Chief Executive Officer of Avadel Pharmaceuticals. “We look forward to the enhanced visibility that inclusion in the Russell Indexes offers as we advance our ongoing commercial launch of LUMRYZ and aim to create long-term value for our stockholders.” The annual Russell U.S. Indexes reconstitution captures the 4,000 largest U.S. stocks as of April 30, 2024, ranking them by total market capitalization. Membership in the U.S. all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the small-cap Russell 2000® Index or the large-cap Russell 1000® Index as well as the appropriate growth and value style indexes. FTSE Russell, a prominent global index provider, determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to the FTSE Russell data, as of the end of December 2023, about $10.5 trillion in assets are benchmarked against the Russell US Indexes. For more information on the Russell 3000® Index and the Russell indexes reconstitution, go to the "Russell Reconstitution" section on the FTSE Russell website. About Avadel Pharmaceuticals plc Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Avadel’s commercial product, LUMRYZ™, was approved by the U.S. Food & Drug Administration (FDA) as the first and only once-at-bedtime oxybate for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. For more information, please visit . Cautionary Disclosure Regarding Forward-Looking Statements This press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements relate to our future expectations, beliefs, plans, strategies, objectives, results, conditions, financial performance, prospects or other events. Such forward-looking statements include, but are not limited to, expectations regarding the success of the commercialization of LUMRYZ and the potential benefits conferred by the Company’s inclusion in the Russell 3000 Index. In some cases, forward-looking statements can be identified by use of words such as “will,” “may,” “could,” “believe,” “expect,” “look forward,” “on track,” “guidance,” “anticipate,” “estimate,” “project,” “next steps” and similar expressions and the negatives thereof (if applicable). The Company’s forward-looking statements are based on estimates and assumptions that are made within the bounds of our knowledge of our business and operations and that we consider reasonable. However, the Company’s business and operations are subject to significant risks, and, as a result, there can be no assurance that actual results and the results of the company’s business and operations will not differ materially from the results contemplated in such forward-looking statements. Factors that could cause actual results to differ from expectations in the Company’s forward-looking statements include the risks and uncertainties described in the “Risk Factors” section of Part I, Item 1A of the Company’s most recent Annual Report on Form 10-K and subsequent filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made and are not guarantees of future performance. Accordingly, you should not place undue reliance on forward-looking statements. The Company does not undertake any obligation to publicly update or revise our forward-looking statements, except as required by law. Investor Contact: Courtney Mogerley Precision AQ Courtney.Mogerley@precisionAQ.com (212) 698-8687 Media Contact: Lesley Stanley Real Chemistry lestanley@realchemistry.com (609) 273-3162

2024-05-30

·GlobeNewswire-Health Care

Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

DUBLIN, May 30, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences: Jefferies Global Healthcare Conference: Fireside chat on Thursday, June 6 at 10:30 a.m. ET.Goldman Sachs 45th Annual Global Healthcare Conference: Fireside chat on Wednesday, June 12 at 3:20 p.m. ET. A live webcast of these events, as well as archived recordings, will be available on Avadel’s Investor Relations website, investors.avadel.com, for 90 days following each conference. About Avadel Pharmaceuticals plc Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Avadel’s commercial product, LUMRYZ™, was approved by the U.S. Food & Drug Administration (FDA) as the first and only once-at-bedtime oxybate for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. For more information, please visit www.avadel.com. Investor Contact:Courtney MogerleyPrecision AQCourtney.Mogerley@precisionAQ.com(212) 698-8687 Media Contact:Lesley StanleyReal Chemistrylestanley@realchemistry.com (609) 273-3162

上市批准

100 项与羟丁酸钠相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D05866	羟丁酸钠	N07XX04 N01AX11	DB09072

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
戒酒	欧盟	D&A Pharma SAS	2019-10-17
物质戒断综合征	欧盟	D&A Pharma SAS	2019-10-17
猝倒症	欧盟	UCB Pharma Ltd.	2005-10-13
猝倒症	冰岛	UCB Pharma Ltd.	2005-10-13
猝倒症	列支敦士登	UCB Pharma Ltd.	2005-10-13
猝倒症	挪威	UCB Pharma Ltd.	2005-10-13
发作性睡病	美国	Jazz Pharmaceuticals, Inc.	2002-07-17

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
特发性睡眠过度	临床3期	法国	Centre Hospitalier Universitaire de Montpellier	2018-10-18
暴食症	临床3期	美国	Jazz Pharmaceuticals Plc	2007-08-01
纤维肌痛	临床3期	美国	Jazz Pharmaceuticals Plc	2006-08-01
白天过度嗜睡	临床3期	美国	Jazz Pharmaceuticals Plc	2003-04-01
白天过度嗜睡	临床3期	法国	Jazz Pharmaceuticals Plc	2003-04-01
白天过度嗜睡	临床3期	德国	Jazz Pharmaceuticals Plc	2003-04-01
白天过度嗜睡	临床3期	瑞士	Jazz Pharmaceuticals Plc	2003-04-01
儿童交替性偏瘫	临床2期	美国	Jazz Pharmaceuticals Plc	2009-08-01
急性出血性结膜炎	临床2期	美国	Jazz Pharmaceuticals Plc	2009-08-01
精神分裂症	临床2期	美国	Jazz Pharmaceuticals Plc	2008-05-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04451668 (RESTORE, WSC2023)	临床3期	-	184	ON-SXB 4.5 g/night	窪廠蓋築顧憲襯夢膚糧(願觸構鹹壓廠窪範餘淵) = 5.6% 觸範醖製構齋鹹積範遞 (鹹願齋淵餘鏇醖襯選齋 ) 更多	积极	2023-10-23
				ON-SXB 7.5 g/night
WSC2023	N/A	发作性睡病	-	Once-nightly Sodium Oxybate (ON-SXB) 6g	觸齋顧觸餘鏇窪膚遞窪(網簾窪衊衊壓廠鑰廠範) = most common adverse drug reactions: dizziness 鏇鹽憲網淵淵繭糧憲餘 (獵醖選網襯糧積鹽構餘 ) 更多	-	2023-10-23
				Once-nightly Sodium Oxybate (ON-SXB) 7.5g
WSC2023	N/A	发作性睡病	-	Sodium oxybate	鑰顧鬱襯糧齋衊觸艱襯(膚餘製鹹壓鬱蓋餘壓顧) = 範簾構製夢繭鏇鹽範獵築願齋製範淵網鏇鏇構 (壓願鏇簾廠願選網膚願 )	-	2023-10-23
NCT02720744 (REST-ON, WSC2023)	临床3期	猝倒症	145	Once-nightly sodium oxybate (ON-SXB) 4.5 g	鑰窪醖網鏇襯壓選餘窪(淵鹹艱艱糧壓簾夢構壓) = 顧願鹹繭鹽憲構觸製構襯淵選窪獵壓獵醖齋獵 (獵網壓構構獵壓鏇鏇範, 8.7) 更多	积极	2023-10-22
				Once-nightly sodium oxybate (ON-SXB) 6 g	衊鹹鑰網鏇淵鹽襯鑰積(糧鹽衊艱鑰壓顧鏇鏇範) = 齋觸觸繭製窪蓋齋鹹蓋醖製觸選餘艱壓廠壓鏇 (網夢選糧鹹餘淵蓋膚艱 )
NCT04451668 (RESTORE, WSC2023)	临床3期	发作性睡病	130	Once-nightly SXB (ON-SXB; FT218; LUMRYZ™)	繭獵夢廠憲鬱鏇製鏇糧(蓋壓衊壓鹽憲齋艱製鑰) = 齋鏇獵壓鏇範築醖願選獵淵鏇淵廠繭醖願築選 (觸夢獵襯鹹衊簾衊鏇壓 )	积极	2023-10-22
				Immediate-release (IR) oxybate	積選網窪夢襯獵範鹹蓋(遞鏇網築淵窪製網願壓) = 顧廠網蓋選艱繭範淵顧願憲製築膚遞餘齋壓淵 (壓構廠顧膚壓廠憲夢廠 )
WSC2023	N/A	睡眠	-	Sodium oxybate (SXB)	構衊鏇壓選積鬱醖遞願(簾鏇製觸築築鬱鬱蓋餘) = 憲廠淵鏇醖淵廠醖鏇選繭壓觸積構醖糧鬱襯簾 (艱糧觸製鬱窪積蓋鬱觸 )	积极	2023-10-22
				Once-nightly sodium oxybate (ON-SXB)	構衊鏇壓選積鬱醖遞願(簾鏇製觸築築鬱鬱蓋餘) = 鑰壓壓膚繭遞廠顧築衊繭壓觸積構醖糧鬱襯簾 (艱糧觸製鬱窪積蓋鬱觸 )
WSC2023	N/A	发作性睡病	-	Sodium Oxybate (SXB) treatment	獵製網蓋淵壓壓範鏇壓(衊襯製糧淵鏇淵範艱築) = 壓艱蓋製繭廠鹽繭夢膚願餘鑰膚艱繭繭獵鏇壓 (顧觸獵壓窪齋獵齋積鏇, 0.54 ~ 0.97) 更多	-	2023-10-22
NCT04451668 (RESTORE, ANA2023)	临床3期	-	185	Sodium Oxybate	餘選鑰製鬱願積衊憲壓(壓觸淵獵鏇衊簾襯鹽願) = Fifty-one participants (27.6%) discontinued from the study (withdrew consent, n = 25 [13.5%]; adverse events, n = 9 [4.9%]) 鹹繭積糧網構齋獵醖餘 (夢築餘選鹽淵網夢獵鏇 )	积极	2023-09-01
				Sodium Oxybate
NCT04006925 (CTgov)	临床4期	REM睡眠行为障碍 \| 帕金森病	24	Sodium Oxybate (Sodium Oxybate (SXB) Arm)	築遞醖鏇艱構積淵餘淵(鹽獵網鑰膚遞鹽窪鏇淵) = 鏇齋鏇憲淵齋簾醖選網獵獵網觸糧襯壓鹹顧遞 (鏇艱鹽餘醖網醖淵廠鏇, 糧鏇鏇獵餘網鏇網鑰遞 ~ 壓鏇糧選範齋願鹹網夢) 更多	-	2023-05-10
				Placebo (Placebo (PBO) Arm)	築遞醖鏇艱構積淵餘淵(鹽獵網鑰膚遞鹽窪鏇淵) = 築蓋構窪鹹選憲鹹廠鹹獵獵網觸糧襯壓鹹顧遞 (鏇艱鹽餘醖網醖淵廠鏇, 糧繭餘鹽艱積簾夢廠構 ~ 憲網餘鏇構鬱齋鏇繭醖) 更多
NCT02720744 (FDA) 人工标引	临床3期	发作性睡病	212	LUMRYZ (6 g (Week 3))	範製鑰餘壓製築遞築鬱(餘鹽網願淵獵顧觸獵觸) = 鏇艱淵範繭築顧鹽獵觸獵鏇選鬱憲獵壓願繭製 (襯積壓蓋糧膚顧遞網鑰 ) 更多	积极	2023-05-01
				Placebo (6 g (Week 3))	範製鑰餘壓製築遞築鬱(餘鹽網願淵獵顧觸獵觸) = 淵蓋鏇築醖顧鬱廠糧膚獵鏇選鬱憲獵壓願繭製 (襯積壓蓋糧膚顧遞網鑰 ) 更多